Forum Agenda
-
Keynote Forum: The Global Journey of China’s Innovation Drugs
-
-
Future-Driven Intelligent R&D–AI for Life Sciences and Drug Discovery
-
The Era of Superintelligent Agents for Chinese Innovative Drugs
-
Panel Discussion: AI-Empowered Four-in-One Translation Platform
-
AI-Driven Innovation Practices in Pharmaceutical Enterprises
-
AI·Intelligent Transformation: From Data Foundation to Scenario Value
-
-
Medicine-Engineering Integration and Innovative Medical Devices
-
Cross-Border Cooperation and China’s New Drug Global Expansion
-
Global Development of Pharma Enterprises and Emerging Market Cooperation
-
China-Japan Cooperation Session: Leveraging Japan’s Market to Boost Overseas Expansion Strategies
-
Legal Safeguard and Value Empowerment for Globalization of Chinese Pharma Enterprises
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
Global BD Cooperation Session for Innovative Drugs – Track 1, 2 & 3
-
Collaboration Between North American and Chinese Innovative Drug Industries
-
Biosimilars Commercialization & Global Launch Session(China Focus)
-
Protheragen Session: Global Biomedical Cross-Border Transactions
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
U.S. Biotech Tensions and the Future Road for Chinese Pharmaceutical Companies Going Global Session
-
July 23, 09:00–17:20
Global Development of Pharmaceutical Companies and Emerging Market Cooperation Session
Stay tuned
Meeting Planner
Lawrence HE Lian:Chief Executive Officer, Rxilient
Frank HONG Tan:Managing Director, Legend Capital
09:00-09:15 Opening and Welcome
Frank HONG Tan:Managing Director, Legend Capital
09:15-09:35 Pharmaceutical Opportunities and Development Trends in Emerging Markets
Qicong HU:Managing Director & Partner, Boston Consulting Group (BCG)
09:35-10:05 Globalization Pathways for Innovative Pharmaceutical Companies
Xiaobin WU:President, BeiGene
10:05-10:25 Rxilient's Strategy and Practice in Emerging Markets
Lawrence HE Lian:Chief Executive Officer, Rxilient
10:25-10:50 Tea break
10:50-11:10 Collaboration and Opportunities between Singapore and China's Innovative Pharmaceutical Industry
Zi Tian PHANG:Head of Shanghai Office, Singapore Economic Development Board (EDB)
11:10-12:00 Roundtable: Pharmaceutical Policies in Southeast Asia and Case Studies on Overseas Commercialization
Brian YANG(Moderator):Chief Commercial Officer, Rxilient
Qingsong WANG:Founder & Chief Executive Officer, Nanjing Delova Biotech Co., Ltd.
Yifeng JIN:Head of Business Development, Chongqing Genrix Biopharmaceutical Co., Ltd.
Yongping PAN:Chief Business Officer, Etana Biotechnologies
Ricky Teo:Chief Operating Officer, Rxilient
12:00-14:00 Lunch
14:00-14:20 Opportunities, Regulatory Environment and Commercialization Experience in the Middle East Market
Hisham OMAR:General Manager, Middle East & North Africa, Rxilient
14:20-14:40 Clinical Trial Ecosystem in Emerging Markets and Opportunities
for Chinese Pharmaceutical Companies
Steven NG:Deputy Director, Business Development, ClinChoice
14:40-15:30 Roundtable: Middle East and Latin America – A Multidimensional Dialogue on Cross-Regional Commercialization, Registration, and Investment
Jessie CHEN(Moderator):Senior Director, Business Development, Rxilient
Hongyi WANG:Vice President, International Business, CanSino Biologics Inc.
Dong WEI:Vice President, Qingfeng Pharmaceutical Group
Nancy TSUI Chung:Head of China Desk, Pinheiro Neto Advogados
Steven NG:Deputy Director, Business Development, ClinChoice
Hisham OMAR:General Manager, Middle East & North Africa, Rxilient
15:30-16:00 Tea break
16:00-16:20 Investment Strategies and Deployment in Emerging Markets for Pharmaceuticals
Frank HONG Tan:Managing Director, Legend Capital
16:20-17:10 Roundtable: Investment Opportunities in Emerging Markets from a Capital Perspective
Fei QI(Moderator):Executive Director, Legend Capital
Xiaohui ZHANG:Deputy Director, China Chamber of Commerce for Import & Export
of Medicines and Health Products
Yao WU:Director, Private Equity, Silk Road Fund
Xuanhe WANG:Investment Officer, Asian Infrastructure Investment Bank (AIIB)
Sylvia ZHOU:Investment Director, True Light Capital
Jin ZHANG:Executive General Manager, Research Department, China International Capital Corporation Limited (CICC)
17:10-17:20 Closing Remarks
Lawrence HE Lian:Chief Executive Officer, Rxilient